CCR5 and melanoma: Furthermore, polymorphism of CCR5, a chemokine receptor preferentially expressed by Th1 T cells and responsible for homing to the site of inflammation via interaction with its ligands has been reported to have clinical relevance; the Δ32 deletion of CCR5 was reported to be associated with decreased survival in patients with melanoma receiving immunotherapy [36].